abstract：PURPOSE:The purpose of this study is to determine the response, tolerability, and long-term outcome of a neoadjuvant platinum-containing regimen for locally advanced breast cancer (LABC) and to search for a correlation between pathologic complete response (pCR) and predefined biomarkers in this cohort. PATIENTS AND ME...

journal_title：Clinical breast cancer

authors： Yerushalmi R,Hayes MM,Gelmon KA,Chia S,Bajdik C,Norris B,Speers C,Hassell P,O'Reilly SE,Allan S,Shenkier TN

更新日期：2009-08-01 00:00:00

abstract：BACKGROUND:Triple-negative breast carcinoma is defined by a primary tumor that is estrogen receptor negative, progesterone receptor negative, and HER2 negative. The current study was performed to determine the relationship of triple-negative tumor status to outcome after breast conservation treatment with radiation. P...

journal_title：Clinical breast cancer

authors： Solin LJ,Hwang WT,Vapiwala N

更新日期：2009-05-01 00:00:00

abstract：BACKGROUND:Postmenopausal women with osteoporosis had a 66% relative risk reduction for invasive breast cancer over 8 years of raloxifene therapy in the randomized, placebo-controlled 4-year MORE (Multiple Outcomes of Raloxifene Evaluation) trial and the CORE (Continuing Outcomes Relevant to Evista) trial, a 4-year fol...

journal_title：Clinical breast cancer

authors： Vogel VG,Qu Y,Wong M,Mitchell B,Mershon JL

更新日期：2009-02-01 00:00:00

abstract：:Post-breast cancer treatment-related angiosarcomas were first observed in lymphedematous extremities after mastectomy and are now being reported with increasing frequency after lumpectomy and radiation. A case history is presented of a BRCA2 carrier who had a postmastectomy chest wall angiosarcoma but had neither ther...

journal_title：Clinical breast cancer

authors： West JG,Weitzel JN,Tao ML,Carpenter M,West JE,Fanning C

更新日期：2008-12-01 00:00:00

abstract：:Multiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous system frequently complicated by devastating neurologic symptoms and progressive disability. Much progress has been made in the development of immunomodulating drugs to help fight the progression of MS. These drugs are believed to wor...

journal_title：Clinical breast cancer

authors： Amaria RN,Corboy JR,Finlayson CA,Robinson WA,Borges VF

更新日期：2008-10-01 00:00:00

abstract：:The perinatal period, childhood, and adolescence are important intervals for breast cancer risk development. Endogenous estrogen exposure is thought to be highest in utero, and exposure to estrogens throughout life plays an important role in increasing breast cancer risk. Some evidence suggests that breast tissue is n...

journal_title：Clinical breast cancer

authors： Ruder EH,Dorgan JF,Kranz S,Kris-Etherton PM,Hartman TJ

更新日期：2008-08-01 00:00:00

abstract：:Primary breast lymphoma is a rare entity. Furthermore, extranodal marginal zone B-cell lymphoma affecting the breast is exceedingly rare. We report a unique case of invasive lobular carcinoma diagnosed simultaneously with an extranodal marginal zone B-cell lymphoma of the breast. A literature review demonstrated 2 rep...

journal_title：Clinical breast cancer

authors： Anavekar NS,Rozen WM,Rowe K,Murphy C

更新日期：2008-06-01 00:00:00

abstract：BACKGROUND:Recent studies have shown that breast cancer detected by screening has a more favorable prognosis than interval breast cancer. To further understand the biologic significance of this finding, we investigated the association of disease recurrence, local and distant, with the method of detection of the primary...

journal_title：Clinical breast cancer

authors： Tchou J,Greshock J,Bergey MR,Sonnad SS,Sargen M,Weinstein S,Czerniecki BJ,Boraas M,Fraker DL,Rosato E,Fox K,Weber B,Solin LJ

更新日期：2008-04-01 00:00:00

abstract：:Chemotherapeutic agents that disrupt the assembly or disassembly of microtubules, including paclitaxel and docetaxel, are among the most commonly prescribed anticancer therapies. However, the utility of taxane-based therapy is limited principally by problems with formulation, slow administration, cumulative neurotoxic...

journal_title：Clinical breast cancer

authors： Andreopoulou E,Muggia F

更新日期：2008-03-01 00:00:00

abstract：:The potential for cardiac toxicity in association with targeted biologic agents was first observed with trastuzumab, a monoclonal antibody that targets the ErbB2/HER2 receptor. In the pivotal trial of trastuzumab in ErbB2-positive metastatic cancer, an increased incidence of serious cardiac events was observed, partic...

journal_title：Clinical breast cancer

authors： Perez EA

更新日期：2008-03-01 00:00:00

abstract：BACKGROUND:Following treatment for breast cancer, many young women are interested in having a child. There are few data available regarding actual fertility and menopausal outcomes in young breast cancer survivors. We evaluated these outcomes among young breast cancer survivors in collaboration with the Young Survival ...

journal_title：Clinical breast cancer

authors： Partridge AH,Gelber S,Peppercorn J,Ginsburg E,Sampson E,Rosenberg R,Przypyszny M,Winer EP

更新日期：2008-02-01 00:00:00

abstract：:A 40-year-old woman, 6 years after mastectomy, lymph node dissection, and locoregional radiation, presented with hepatic metastases, pruritus, and jaundice. Physical examination revealed uniformly jaundiced skin and no arm lymphedema. Ultrasonography confirmed progressive hepatic metastases with no evidence of intrahe...

journal_title：Clinical breast cancer

authors： Tsang RY,Mackey JR

更新日期：2007-12-01 00:00:00

abstract：PURPOSE:HER2 gene amplification and overexpression is associated with aggressive breast cancer and poor prognosis. Accurate HER2 testing of patients with breast cancer before treatment is important to ensure that as many patients with HER2-positive breast cancer as possible receive the most appropriate treatment and th...

journal_title：Clinical breast cancer

authors： Papadopoulos S,Kouvatseas G,Skarlos D,Malamos N,Delliou E,Saratsiotou I,Ardavanis A,Mavroudis D,Skarpidi E,Arapantoni P,Karyda I,Patakioyta F,Aravantinos G,Razis E,Fountzilas G,Kosmidis P

更新日期：2007-10-01 00:00:00

abstract：PURPOSE:In order to evaluate the feasibility of dose-dense docetaxel followed by dose-dense AC (doxorubicin/cyclophosphamide) as adjuvant chemotherapy for operable breast cancer, we conducted a phase II study. PATIENTS AND METHODS:In cohort 1, 28 patients received docetaxel 100 mg/m2 followed by doxorubicin 60 mg/m2 w...

journal_title：Clinical breast cancer

authors： Lambert-Falls R,Modugno S

更新日期：2007-08-01 00:00:00

abstract：:More than 220,000 women will be diagnosed with breast cancer this year, and approximately 75% of these women will be long-term survivors of this disease. Survival has improved largely because of advances in adjuvant hormone therapy and chemotherapy, as well as early detection strategies. Because most women will receiv...

journal_title：Clinical breast cancer

authors： Rugo HS

更新日期：2007-07-01 00:00:00

abstract：PURPOSE:The objective of this study was to evaluate whether p27kip1 downregulation is a prognostic factor in patients with inflammatory breast carcinoma (IBC). PATIENTS AND METHODS:Fifty-eight patients with IBC were treated between January 1994 and July 2002. Median age was 49 years. Thirty-eight patients had baseline...

journal_title：Clinical breast cancer

authors： Gonzalez-Angulo AM,Guarneri V,Gong Y,Cristofanilli M,Morales-Vasquez F,Sneige N,Hortobagyi GN,Esteva FJ

更新日期：2006-10-01 00:00:00

abstract：BACKGROUND:Adjuvant trastuzumab improves relapse-free survival in HER2-overexpressing breast cancer but is associated with cardiac toxicity. This phase II study was undertaken to determine the neoadjuvant clinical and pathologic response rate and the acute and chronic cardiac toxicity of trastuzumab given with weekly p...

journal_title：Clinical breast cancer

authors： Kelly H,Kimmick G,Dees EC,Collichio F,Gatti L,Sawyer L,Ivanova A,Dressler L,Graham ML,Carey LA

更新日期：2006-08-01 00:00:00

abstract：:Chyle fistula is not a well-known complication of axillary dissection in patients with breast cancer. Although rare, this complication can occur as a result of anatomic variation of the thoracic duct and its venous anastomosis. Injury to the lateral terminating branches or lymphatic trunk, leading to retrograde chyle ...

journal_title：Clinical breast cancer

authors： Donkervoort SC,Roos D,Borgstein PJ

更新日期：2006-06-01 00:00:00

abstract：:Breast carcinoma in men is rare and comprises approximately 1% of all breast cancer cases. In contrast to the increase in the detection rate of ductal carcinoma in situ (DCIS) in women resulting from the wide use of screening mammography programs, the rate of male DCIS is still small and represents approximately 5% of...

journal_title：Clinical breast cancer

authors： Pappo I,Wasserman I,Halevy A

更新日期：2005-10-01 00:00:00

abstract：:The development of third-generation aromatase inhibitors (AIs) has brought about a major change in the therapeutic approach to patients with hormone-sensitive breast cancer. In randomized clinical trials, each of the third-generation AIs has demonstrated efficacy in the adjuvant treatment of postmenopausal women with ...

journal_title：Clinical breast cancer

authors： Henderson IC,Piccart-Gebhart MJ

更新日期：2005-08-01 00:00:00

abstract：:Primary squamous cell carcinoma (SCC) of the breast is an extremely rare tumor. It is diagnosed when the malignant cells are entirely of squamous type, the tumor is independent from overlying skin, and other primary SCC sites are excluded. This report presents clinical, radiologic, and histologic correlative findings ...

journal_title：Clinical breast cancer

authors： Siegelmann-Danieli N,Murphy TJ,Meschter SC,Stein ME,Prichard J

更新日期：2005-08-01 00:00:00

abstract：:Intravenous bisphosphonates are the preferred treatment to prevent skeletal complications for patients with breast cancer and bone metastases. Pamidronate, a single-nitrogen bisphosphonate, was the early standard of care for such patients based on 2 large, placebo-controlled trials involving 754 patients. Zoledronic a...

journal_title：Clinical breast cancer

authors： Gordon DH

更新日期：2005-06-01 00:00:00

abstract：:In a review of current information on aromatase inhibitors (AIs) and their use in breast cancer treatment and prevention, published reports were obtained through a Medline search. Tamoxifen, a selective estrogen receptor modulator, is approved for use in metastatic breast cancer (MBC), the adjuvant treatment of breast...

journal_title：Clinical breast cancer

authors： Kalidas M,Brown P

更新日期：2005-04-01 00:00:00

abstract：:Fulvestrant, an estrogen receptor antagonist that downregulates the estrogen receptor but has no known agonist effects, has been evaluated in 2 randomized trials involving postmenopausal women with hormone receptor-positive, progressive advanced-stage breast cancer after disease progression with antiestrogen therapy. ...

journal_title：Clinical breast cancer

authors： Jones SE,Pippen J

更新日期：2005-04-01 00:00:00

abstract：:Neoadjuvant chemotherapy has been employed increasingly in operable breast cancer during recent years. Several randomized trials showed that the chances of breast conserving therapy are being enhanced, and that survival was not compromised by primary systemic therapy compared to adjuvant treatment. Apart from the surg...

journal_title：Clinical breast cancer

authors： Huober J,Krainick-Strobel U,Kurek R,Wallwiener D

更新日期：2004-12-01 00:00:00

abstract：:Women with germline mutations in BRCA1 or BRCA2 are known to be at substantially elevated risk for breast cancer. With increasing acceptance of genetic testing, significant numbers of mutation carriers are being identified, but evidence-based guidelines for the management of women at hereditary risk are lacking. This ...

journal_title：Clinical breast cancer

authors： Robson M

更新日期：2004-10-01 00:00:00

abstract：:This article discusses the rationale for 2 methods of making estimates of the benefit of letrozole as extended adjuvant hormonal therapy after 5 years of tamoxifen. It uses information from the Overview metaanalyses to develop general rules for making estimates of remaining risk of relapse for women completing 5 years...

journal_title：Clinical breast cancer

authors： Ravdin PM,Davis GJ

更新日期：2004-10-01 00:00:00

abstract：:The elderly population has been neglected by the traditional approach to clinical breast cancer research. Elderly women have been underrepresented in breast cancer clinical trials, with the majority of studies being restricted to patients aged < 70 years. Elderly patients frequently have comorbidities and/or impaired ...

journal_title：Clinical breast cancer

authors： Biganzoli L,Aapro M,Balducci L,Crivellari D,Minisini A,Piccart M

更新日期：2004-08-01 00:00:00

abstract：:The 26S proteasome is an adenosine triphosphate-dependent multicatalytic protease that is responsible for most nonlysosomal intracellular protein degradation. To be selected for proteasomal degradation, proteins must be previously tagged with a polyubiquitin chain, which is then recognized by the proteasome; the ubiqu...

journal_title：Clinical breast cancer

authors： Cardoso F,Ross JS,Picart MJ,Sotiriou C,Durbecq V

更新日期：2004-06-01 00:00:00

abstract：:During the past decade, improvements in treatment-planning tools, computer and imaging technologies, and new therapeutic modalities have allowed radiation to be delivered in a conformal fashion while minimizing treatment toxicity. It is important that physicians involved in breast cancer treatment recognize the numero...

journal_title：Clinical breast cancer

authors： Frank SJ,McNeese MD,Strom EA,Perkins G,Salehpour M,Schechter N,Buchholz TA

更新日期：2004-02-01 00:00:00

abstract：:Over the past 30 years, much progress has been made in adjuvant chemotherapy for patients with early-stage breast cancer. The introduction of anthracyclines and, recently, taxanes has significantly improved the efficacy of adjuvant chemotherapy and has provided useful insight regarding future development of even more ...

journal_title：Clinical breast cancer

authors： Mamounas EP,Geyer CE Jr,Swain SM

更新日期：2004-01-01 00:00:00

abstract：:Trastuzumab/chemotherapy combinations have already shown superior results in metastatic breast cancer patients. The purpose of this study is to determine the clinical efficacy of neoadjuvant trastuzumab and docetaxel in women with locally advanced breast cancer, with or without metastatic disease. Treatment-naive wome...

journal_title：Clinical breast cancer

authors： Van Pelt AE,Mohsin S,Elledge RM,Hilsenbeck SG,Gutierrez MC,Lucci A Jr,Kalidas M,Granchi T,Scott BG,Allred DC,Chang JC

更新日期：2003-12-01 00:00:00

abstract：:Breast-conserving therapy (BCT) consists of segmental mastectomy followed by postoperative radiation therapy (RT) to the whole breast. At least 6 prospective randomized trials have proven the equivalence of BCT to mastectomy. However, BCT remains underused and, most importantly, a sizable proportion of patients with i...

journal_title：Clinical breast cancer

authors： Truong MT,Hirsch AE,Formenti SC

更新日期：2003-10-01 00:00:00

abstract：:This article attempts to provide the reader with a complete overview of topoisomerase (topo) II alpha as a marker for predicting the efficacy of anthracyclines in patients with breast cancer. In the first section of this article, in vitro data supporting the predictive value of topo II alpha are reviewed. Interestingl...

journal_title：Clinical breast cancer

authors： Di Leo A,Isola J

更新日期：2003-08-01 00:00:00

abstract：:Despite the widespread use of trastuzumab in the management of patients with HER2-overexpressing metastatic breast cancer, its optimal duration of administration is unknown. We retrospectively reviewed the medical records of 80 such patients who received trastuzumab monotherapy or combination chemotherapy beyond disea...

journal_title：Clinical breast cancer

authors： Fountzilas G,Razis E,Tsavdaridis D,Karina M,Labropoulos S,Christodoulou C,Mavroudis D,Gogas H,Georgoulias V,Skarlos D

更新日期：2003-06-01 00:00:00

abstract：:For detecting and diagnosing breast cancer at its earliest stage, mammography is the most sensitive technique currently available and is therefore the method of choice. Screen-film mammography has been used successfully as a screening test for breast cancer for > 2 decades. However, conventional mammography has substa...

journal_title：Clinical breast cancer

authors： Shah AJ,Wang J,Yamada T,Fajardo LL

更新日期：2003-04-01 00:00:00

abstract：:[18F]fluorodeoxyglucose positron emission tomography (FDG-PET) is a metabolic imaging modality that has increasing applications in oncology, neurology, and cardiology. Among the oncology applications, breast cancer is one of the most extensively studied diseases. FDG-PET has been performed for diagnosis, staging, and ...

journal_title：Clinical breast cancer

authors： Wu D,Gambhir SS

更新日期：2003-04-01 00:00:00

abstract：:Mucin-1 (MUC-1) is a high-molecular-weight glycoprotein rich in serine and threonine residues that are O-glycosylated. Expression of MUC-1 is increased in breast, ovarian, and other adenocarcinomas, and altered glycosylation results in exposure of novel peptide epitopes and the expression of tumor-associated carbohydr...

journal_title：Clinical breast cancer

authors： Miles D,Papazisis K

更新日期：2003-02-01 00:00:00

abstract：:Traditionally in the treatment of primary breast cancer, axillary lymph node dissection (ALND) plays an important role. However, a substantial and increasing percentage of patients appear to have no nodal involvement and have been subjected to ALND unnecessarily. The first reason to perform an ALND is axillary nodal s...

journal_title：Clinical breast cancer

authors： Bourez RL,Rutgers EJ,Van De Velde CJ

更新日期：2002-12-01 00:00:00

abstract：:Currently, the interest in cognitive functioning following chemotherapy is rapidly expanding as is reflected in a growing number of published studies on this topic. Although most studies are indicative of cognitive deficits after chemotherapy, definite conclusions on the role of chemotherapy on cognitive function can ...

journal_title：Clinical breast cancer

authors： Schagen SB,Muller MJ,Boogerd W,Van Dam FS

更新日期：2002-12-01 00:00:00